Absence of Evidence of Beneficial Effects of Human Milk-Based Fortifier: A Bayesian Model-Averaged Meta-Analysis
Maurice J Huizing1, Giulia Vizzari2, František Bartoš3
1Division of Neonatology, Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Center (MUMC+), School for Oncology and Reproduction (GROW), Maastricht University, Maastricht, the Netherlands.
Aim:
Human milk-based fortifiers (HMBFs) have been adopted in neonatal care despite limited efficacy data. Our objective was to conduct a Bayesian re-analysis of the current evidence on the protective effect of HMBF against necrotising enterocolitis (NEC, stage II-III).
Methods:
We searched for randomised controlled trials (RCTs) comparing HMBF versus bovine milk-based fortifier (BMBF) in infants with gestational age < 32 weeks or birthweight < 1500 g. Bayesian model-averaged (BMA) meta-analysis was used to calculate Bayes factors (BFs). The BF10 is the ratio of the probability of the data under the alternative hypothesis (H1, presence of effect) over the probability of the data under the null hypothesis (H0, absence of effect).
Results:
We included 3 RCTs (405 infants). The BMA analysis did not show conclusive evidence in favour of H1 (BF10 > 3) or in favour of H0 (BF10 < 1/3) for NEC (BF10 = 0.86), mortality (BF10 = 1.07), late onset sepsis (BF10 = 0.69), bronchopulmonary dysplasia (BPD, BF10 = 0.92), or severe retinopathy of prematurity (ROP, BF10 = 0.75).
Conclusions:
The extant corpus of RCTs does not provide sufficient evidence to either confirm or exclude a potential effect of HMBF compared with BMBF on the risk of NEC, mortality, sepsis, BPD, or severe ROP.
Related Concept Videos
Bias in Epidemiological Studies
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Confounding in Epidemiological Studies
Regression Toward the Mean
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...


